Spago Nanomedical AB (DE:7UX)
FRANKFURT:7UX
7UX Stock Chart & Stats
€0.01
>-€0.01(-11.76%)
At close: 4:00 PM EST
€0.01
>-€0.01(-11.76%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.41M
Enterprise Value€9.65M
Total Cash (Recent Filing)€29.67M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding661,572,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.42
Price to Sales (P/S)99.92
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€93.78K
Bulls Say, Bears Say
Bulls Say
Focused Pipeline In Imaging & TheranosticsConcentrated expertise in nanoparticle-based imaging and theranostics targets high-barrier, specialized markets with strong clinical value. This technological focus increases partnership and licensing appeal, and positions the company in areas where successful clinical proof could yield durable commercial opportunities.
Narrowing Net LossesA sustained reduction in net loss suggests improving cost control or operating efficiency as development progresses. If maintained, this trend reduces future funding needs, improves investor optionality for partnerships or licensing, and supports a clearer path toward durable operating sustainability.
Debt-free Balance SheetA zero-debt capital structure materially lowers near-term financial risk and interest obligations, giving management more flexibility to prioritize R&D, clinical programs and partnership negotiations. Over 2–6 months this extends runway versus peers with leverage and reduces refinancing pressure.
Bears Say
Erosion Of Equity And Negative ROEDeclining shareholder equity and persistently negative ROE reflect erosion of investor capital and reduced balance sheet resilience. Over months this limits strategic flexibility, makes future financing more dilutive or costly, and signals structural difficulty converting R&D investment into shareholder value.
Small, Volatile And Declining RevenueMaterial revenue volatility and a sharp year-over-year decline signal limited commercial traction and weak recurring cash generation. This undermines the company’s ability to self-fund development, increases reliance on external capital, and weakens the business case for sustainable operations absent successful partnering.
Persistent Cash BurnOngoing negative operating cash flow indicates the business is cash-consuming and reliant on external financing. Over a multi-month horizon this raises dilution and funding-risk concerns, constrains discretionary spending on trials, and can force hurried partnerships or unfavorable financing terms.
7UX FAQ
What was Spago Nanomedical AB’s price range in the past 12 months?
Spago Nanomedical AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Spago Nanomedical AB’s market cap?
Spago Nanomedical AB’s market cap is €6.41M.
When is Spago Nanomedical AB’s upcoming earnings report date?
Spago Nanomedical AB’s upcoming earnings report date is May 07, 2026 which is in 36 days.
How were Spago Nanomedical AB’s earnings last quarter?
Spago Nanomedical AB released its earnings results on Feb 05, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Spago Nanomedical AB overvalued?
According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued.
Does Spago Nanomedical AB pay dividends?
Spago Nanomedical AB does not currently pay dividends.
What is Spago Nanomedical AB’s EPS estimate?
Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spago Nanomedical AB have?
Spago Nanomedical AB has 661,572,800 shares outstanding.
What happened to Spago Nanomedical AB’s price movement after its last earnings report?
Spago Nanomedical AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Spago Nanomedical AB?
Currently, no hedge funds are holding shares in DE:7UX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spago Nanomedical AB
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Technical Analysis
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
Modus Therapeutics Holding AB
―
NextCell Pharma AB
―